# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023Biotechnology leader Camero...
- SEC Filing
- SEC Filing
Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therap...
Wells Fargo analyst Yanan Zhu maintains Aeglea BioTherapeutics (NASDAQ:AGLE) with a Equal-Weight and raises the price target...